Literature DB >> 27392443

Pediatric thalamic glioma with H3F3A K27M mutation, which was detected before and after malignant transformation: a case report.

Kenichi Ishibashi1, Takeshi Inoue2, Hiroko Fukushima2, Yusuke Watanabe3, Yoshiyasu Iwai3, Hiroaki Sakamoto4, Kai Yamasaki5, Jyunichi Hara5, Tomoko Shofuda6, Daiksuke Kanematsu7, Ema Yoshioka6, Yonehiro Kanemura7,8.   

Abstract

PURPOSE: Histone H3.3 (H3F3A) mutation in the codon for lysine 27 (K27M) has been found as driver mutations in pediatric glioblastoma and has been suggested to play critical roles in the pathogenesis of thalamic gliomas and diffuse intrinsic pontine gliomas. We report a case of thalamic glioma with H3F3A K27M mutation, which was detected in both the primary tumor diagnosed as diffuse astrocytoma obtained during the first surgery and also in the tumor diagnosed as anaplastic astrocytoma obtained at the second surgery. CASE
PRESENTATION: A 14-year-old girl presented with mild headache. Magnetic resonance imaging (MRI) showed a small intraaxial lesion in the left thalamus, which increased in size. Stereotactic tumor biopsy was performed 2 years after the initial diagnosis, and a pathological diagnosis of diffuse astrocytoma (WHO grade 2) was made. The tumor grew further and showed contrast enhancement on MRI despite 16 months of chemotherapy. Surgical removal via the transcallosal approach was then performed, and postoperative pathological diagnosis was anaplastic astrocytoma (WHO grade 3), indicating malignant transformation of the tumor. Molecular diagnosis of tumor tissue obtained at first and second surgeries revealed H3F3A K27M mutation in both primary and secondary specimens.
CONCLUSION: This report demonstrates minute neuroradiological and pathological features of malignant transformation from thalamic low grade glioma with H3F3A K27M mutation. It is noteworthy that this mutation was found in this case when the tumor was still a low-grade glioma. Tissue sampling for genetic analysis is useful in patients with thalamic gliomas to predict the clinical course and efficacy of treatments.

Entities:  

Keywords:  H3F3A K27M mutation; Malignant transformation; Thalamic gliomas

Mesh:

Substances:

Year:  2016        PMID: 27392443     DOI: 10.1007/s00381-016-3161-8

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  26 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

Review 2.  Advances in the development of histone lysine demethylase inhibitors.

Authors:  Tamara Maes; Elena Carceller; Jordi Salas; Alberto Ortega; Carlos Buesa
Journal:  Curr Opin Pharmacol       Date:  2015-06-05       Impact factor: 5.547

3.  Thalamic tumors in children.

Authors:  V Cuccia; J Monges
Journal:  Childs Nerv Syst       Date:  1997-10       Impact factor: 1.475

4.  Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases.

Authors:  Carla Fernandez; André Maues de Paula; Carole Colin; Benoît Quilichini; Corinne Bouvier-Labit; Nadine Girard; Didier Scavarda; Gabriel Lena; Dominique Figarella-Branger
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

5.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

6.  Diagnostic challenges of primary thalamic gliomas-identification of a minimally enhancing neuroradiological subtype with aggressive neuropathology and poor clinical outcome.

Authors:  K M Kurian; Y Zhang; H R Haynes; N A Macaskill; M Bradley
Journal:  Clin Neuroradiol       Date:  2013-05-25       Impact factor: 3.649

7.  Surgical management of thalamic gliomas: case selection, technical considerations, and review of literature.

Authors:  Narayanam Anantha Sai Kiran; Sumit Thakar; Ravi Dadlani; Dilip Mohan; Sunil Valentine Furtado; Nandita Ghosal; Saritha Aryan; Alangar S Hegde
Journal:  Neurosurg Rev       Date:  2013-01-25       Impact factor: 3.042

8.  Feasibility and advisability of resections of thalamic tumors in pediatric patients.

Authors:  A Leland Albright
Journal:  J Neurosurg       Date:  2004-05       Impact factor: 5.115

9.  Thalamic tumors in children: a reappraisal.

Authors:  Stephanie Puget; Darach W Crimmins; Matthew R Garnett; Jacques Grill; Ricardo Oliveira; Nathalie Boddaert; Alison Wray; Arielle Lelouch-Tubiana; Thomas Roujeau; Federico Di Rocco; Michel Zerah; Christian Sainte-Rose
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

10.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.

Authors:  David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily
Journal:  Acta Neuropathol       Date:  2015-09-23       Impact factor: 17.088

View more
  2 in total

1.  Pediatric posterior fossa incidentalomas.

Authors:  Danil A Kozyrev; Shlomi Constantini; Deki Tsering; Robert Keating; Sharif Basal; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2019-09-06       Impact factor: 1.475

2.  Malignant transformation of a conservatively managed incidental childhood cerebral mass lesion: controversy regarding management paradigm.

Authors:  Jehuda Soleman; Jonathan Roth; Zvi Ram; Michal Yalon; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2017-08-14       Impact factor: 1.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.